Boehringer Ingelheim signs deal to manufacture biomedicine for BeiGene

By Feng Jianmin | September 2, 2014, Tuesday |

Online Edition

BOEHRINGER Ingelheim today signed an agreement to manufacture biopharmaceuticals for Beijing-based biotech company BeiGene in BI’s newly built Zhangjiang facility as Shanghai plans a pilot program to allow contract manufacturing of biomedicine.

The facility is expected to start producing cancer drugs for BeiGene’s next year, the companies said, and it will eventually become BI’s fourth manufacturing base to support the global market.

BI said that it is confident to acquire administrative approval for the contract manufacturing organization (CMO) license in its 500 million yuan (US$81.9 million) joint investment in Zhangjiang with Shanghai Zhangjiang Biotech and Pharmaceutical Base Development Co.

“By bringing our experience in China, we are able to support more Chinese biopharmaceutical companies in developing and manufacturing biomedicines, thus providing more medication of high quality to Chinese patients,” said Hubertus von Baumbach, member of BI’s board of managing directors.

Shanghai has been mulling since 2013 plans to be the first city in China to open up biophamaceuticals to expand manufacturing capacity for the sector.

The program will allow a contract manufacturer to act as a producing and shipping unit on behalf of a hiring company.

Business Manufacturing

About Us
|
Terms of Use
|
RSS
|
Privacy Policy
|
Contact Us
|
Shanghai Call Center: 962288
|
Tip-off hotline: 52920043

沪ICP证：沪ICP备05050403号-1
|
互联网新闻信息服务许可证：31120180004
|
网络视听许可证：0909346
|
广播电视节目制作许可证：沪字第354号
|
增值电信业务经营许可证：沪B2-20120012

Boehringer Ingelheim signs deal to manufacture biomedicine for BeiGene

Email this to your friend